The oxidative pentose phosphate pathway is poorly developed in the rat heart compared with other organs, since the activity of glucose-6-phosphate dehydrogenase (G-6-PDH), the first and rate-limiting enzyme of the oxidative pentose phosphate pathway, is low. As a consequence, the available pool of 5-phosphoribosyl-l-pyrophosphate and the rate of adenine nucleotide biosynthesis are limited. Isoproterenol, 24 hours after subcutaneous administration at 0.1, 1, and 25 mg/kg, stimulated the activity of G-6-PDH in whole hearts dose-dependently from 4.3±0.16 (control) to 6.6± 0.35, 10.3+±0.82, and 11.5+±0.56 units/g protein, respectively. The activity of 6-phosphogluconate dehydrogenase, another of the enzymes in the oxidative pentose phosphate pathway, remained unchanged. G-6-PDH activity started to increase 12 hours after isoproterenol application, when the glycogenolytic and functional response was over, and reached a peak value between 24 and 48 hours. This stimulating effect was also demonstrated in cardiac myocytes that were isolated 28 hours after isoproterenol application. /-Receptor blockade with atenolol reduced the isoproterenol-induced increase in cardiac G-6-PDH activity by 90%o. Cycloheximide, which inhibits translation, and actinomycin D, which interferes with transcription, attenuated it by 83% and 78%, respectively. These results indicate that cardiac /-adrenergic receptors and enzyme protein synthesis are involved in this effect. Other /3-sympathomimetic agents such as dopamine, dobutamine, fenoterol, salbutamol, and terbutaline also stimulated myocardial G-6-PDH activity in a time-and dose-related manner. The calcium antagonist D 600 (gallopamil) reduced the isoproterenol-elicited stimulation by 65%, and verapamil blunted the fenoterol-induced increase by 50%6. This suggests that Ca2' ions also contribute to the stimulation of the cardiac oxidative pentose phosphate pathway. (Circulation Research 1990;67:1525-1534 T he oxidative pentose phosphate pathway (PPP) is important, since it is the link between carbohydrate and fatty acid as well as purine and pyrimidine nucleotide metabolism (Figure 1 ). Glucose-6-phosphate (G-6-P), originating from glycogenolysis or from glucose taken up by the myocardial cell, is metabolized predominantly via glycolysis. A certain portion, however, enters the oxidative branch of the PPP of which glucose-6-phosphate dehydrogenase (G-6 -PDH) is the first and rate-limiting enzyme.' This pathway has two major functions to fulfill: 1) It provides reducing equivalents in the form of NADPH, which can be used for the synthesis of free fatty acids and for the conversion of oxidized glutathione to reduced glutathione. This is important for the detoxification of reactive oxygen species via glutathione peroxidase.2 2) In this pathway, ribose-5-phosphate is generated, which can be transformed to 5-phosphoribosyl-1-pyrophosphate (PRPP), and this is an essential precursor substance for the synthesis of both pyrimidine and purine nucleotides. There are connections between the oxidative PPP and glycolysis at two levels via the transaldolase and transketolase reactions.
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lates adenine nucleotide biosynthesis.6 It has been demonstrated previously that an experimentally induced decline in the cardiac ATP pool can be attenuated or even prevented by application of ribose. [6] [7] [8] As to the regulation of this pathway, it is known from studies on the liver that G-6-PDH is regulated by the NADP+/NADPH ratio,1 which exerts a "fine control." G-6-PDH is always inhibited by NADPH,9 and this inhibition can be overcome by oxidized glutathione.' It has been demonstrated that the flow through the oxidative PPP in the isolated perfused rat heart can be enhanced acutely and rapidly by an oxidizing agent that increases the oxidized glutathione level and the NADP+/NADPH ratio.10
It was the primary aim of this study to assess quantatively the capacity of the oxidative PPP in the rat heart compared with other organs. To do this, the activity of G-6-PDH, the available pool of PRPP, and the rate of adenine nucleotide biosynthesis were determined ( Figure 1 
Measurement of Metabolic Parameters
The activities of G-6-PDH (EC 1.1.1.49) and 6-PGDH (EC 1.1.1.44) were measured according to the methods of Glock and McLean.13,14 After various periods of in vivo exposure to the different substances, the rats were anesthetized with ether, and a cannula was placed in the ascending aorta after thoracotomy and tightly fixed there. The hearts were quickly excised, and the coronary arteries were perfused via the cannula with an ice-cold KCI solution (0.15 M containing 8 ml of 0.02 M KHCO3/l) to remove blood and to stop the beating of the heart. After homogenization of the hearts in the perfusion medium, pH adjustment (7.0), and centrifugation (ultracentrifuge model L5 -65, Beckman Instruments, Inc., Fullerton, Calif.) at 20,000 rpm for 30 minutes, the supernatants were dialyzed overnight. The enzyme activities were then measured spectrophotometrically. Protein concentration in the dialysate was determined by using the modified biuret reaction.15 The mean specific activity of both enzymes was expressed as units per gram protein.
Levels of cyclic AMP (cAMP) were determined according to the method of Gilman. 16 The content of G-6-P was measured using the method of Lang and Michal. 17 The available pool of PRPP was assessed from the radioactivity of adenine nucleotides after 5, 10, and 15 minutes of in vivo exposure of the rats to intravenously injected [8-1'4C]adenine or [U-14C]adenine. Since PRPP is consumed in the reaction by which adenine is converted to AMP catalyzed by adenine phosphoribosyltransferase (EC 2.4.2.7) and since AMP is in rapid equilibrium with ADP and ATP via the myokinase reaction (EC 2.7.4.3), the total radioactivity of the adenine nucleotides ATP+ADP+AMP is an indirect measure of the available pool of PRPP.6 After the indicated periods of vivo exposure, the hearts were excised in ether anesthesia and frozen in liquid nitrogen. After tissue extraction, adenine derived from adenine nucleotides by hydrolysis was separated, and the radioactivity was counted in a tri-carb liquid scintillation spectrometer (model 3380, Packard Instruments, Downers Grove, Ill.).
The de novo synthesis (biosynthesis) of adenine nucleotides was measured on the basis of the incorporation of [1-`4C]glycine (250 ,uCi/kg body wt injected into the tail vein) into adenine nucleotides. After an in vivo exposure time of 60 minutes, the hearts were excised in ether anesthesia and frozen in liquid nitrogen; the radioactivity was measured after extraction, separation, and purification of the adenine nucleotides, according to methods described earlier. 3 Rates of de novo synthesis were calculated by relating the total radioactivity of adenine nucleotides due to the incorporation of [1-14C] glycine to the mean specific activity of the tissue glycine precursor pool, which was determined with an amino acid analyzer (model BC 200, BioCal Munchen, F.R.G.). Rates of protein synthesis were determined in the same hearts in which adenine nucleotide biosynthesis was measured by relating the radioactivity of total cardiac proteins to the mean specific activity of the amino acid precursor pool. ' 
Isolation of Cardiac Myocytes
Rats were anesthetized with thiopental sodium (Trapanal, Byk Gulden) and heparinized 28 hours after subcutaneous injection of NaCI or isoproterenol (25 mg/kg). The chest was opened, and the hearts were quickly removed. The aorta was immediately cannulated and attached to a modified Langendorff apparatus. Isolated myocytes were prepared by perfusion with collagenase type II obtained from Sigma Chemie GmbH in calcium-free Joklik medium as described by Bishop and Drummond.20 The right ventricle was separated from the septum by sharp dissection and minced into calcium-free Joklik media containing 0.01 mM EGTA, poured through nylon mesh (250 ,tm), and fixed in glutaraldehyde for visual quality control of the isolation procedure using an Axioskop microscope (Zeiss, Oberkochen, F.R.G.). The left ventricles of hearts from two identically treated rats were minced immediately into the KCI solution (0.15 M containing 8 ml of 0.02 M KHCOJ1) that was used for homogenization and poured through nylon. After correcting the pH and centrifugation, the supernatants were dialyzed overnight. G-6-PDH activity was then measured spectrophotometrically, as described earlier ( Figure 2 ). There was a parallel behavior of these three parameters in the organs examined. They were all highest in kidney, followed by liver, heart, and skeletal muscle. From these results, it appears that the capacity of the oxidative PPP is lowest in heart and skeletal muscle. To substantiate this, ribose was administered. It did not alter the PRPP availability and adenine nucleotide biosynthesis in kidney and liver. In heart and skeletal muscle, however, there was a marked increase ( Figure 2 , middle and bottom panels).
It was now of interest to determine whether the oxidative PPP in the heart could be enhanced in intact rats so that more PRPP would be provided for nucleotide metabolism. In a first attempt, the effect of isoproterenol on the activity of cardiac G-6-PDH and 6-PGDH was tested. Isoproterenol stimulated the activity of G-6-PDH in a dose-dependent man- ner but had no influence at all on the activity of 6-PGDH ( Table 1) . The changes in metabolic and functional parameters that occurred over a time period of 72 hours subsequent to the highest dose of isoproterenol are shown in Figure 3 . There was an immediate increase in the cAMP content as well as in the content of G-6-P. Parallel to these metabolic alterations, heart rate and LV dP/dtmx were also elevated. After 12 and 24 hours, these metabolic and functional parameters had returned to the control level. However, adenine nucleotide biosynthesis, which was also enhanced very early, remained elevated, although at a somewhat lower level. With a time lag there was an increase in cardiac protein synthesis, and when this was clearly enhanced, the activity of myocardial G-6-PDH started to be stimulated. The peak was reached quite late, after 24 and 48 hours.
After 28 hours of in vivo exposure to isoproterenol (25 mg/kg, subcutaneously applied), G-6-PDH activity was measured in freshly isolated cardiac myocytes obtained from the left ventricle and compared with that of NaCl-injected rats. In myocytes from control rats, it was 0.3+±0.05 units/g protein (n=7); in those from isoproterenol-treated rats, it was significantly increased (p<0.0005) to 3.2+0.55 units/g protein (n=6). From the time course (Figure 3) , it is suggestive that activation of G-6-PDH in the heart is dependent on protein synthesis and thus may reflect an increased new synthesis of enzyme protein. Therefore, the effect of inhibitors of protein synthesis on G-6-PDH was examined. Cycloheximide and actinomycin D, which had no effect on cardiac G-6-PDH activity by themselves, attenuated the isoproterenol-induced increase by 83% and 78%, respectively (Table 2) . /3-Receptor blockade with atenolol reduced the isoproterenol-elicited enhancement of G-6-PDH activity by 90%. The calcium antagonist compound D 600 (gallopamil) blunted it by 65% (Figure 4) . When dopamine was administered either as subcutaneous injection or as continuous intravenous infusion, there was a time-and dose-dependent stimulation of cardiac G-6-PDH activity, which was almost completely abolished with atenolol (Table 3) . Dobutamine also stimulated G-6-PDH activity, though not as markedly as did dopamine (Table 3) .
To examine whether the available pool of PRPP may also be affected by these substances, the incorporation of [14C]adenine into myocardial adenine degrees ( Figure 6 ). None of these substances had an influence on cardiac 6-PGDH activity (data not shown).
Since fenoterol had the most marked effects, further experiments were done with this drug. Fenoterol stimulated cardiac G-6-PDH activity in a dose-dependent manner (Figure 7 ). To examine whether this increase can be influenced by blocking the calcium channel, the calcium antagonist verapamil was used. Verapamil antagonized the hemodynamic response to fenoterol effectively. Heart rate and LV systolic pressure were even lower than control values when verapamil was administered in combination with fenoterol ( Figure 8 ). Yet, G-6-PDH activity was still increased by 30% in the presence of verapamil, while the pressure-rate product was even lower than control values (Figure 9 ). Our comparative studies have shown that the capacity of the oxidative PPP was lower in heart and skeletal muscle than in kidney and liver. The assessment of this pathway was based on three independent parameters, G-6-PDH activity, PRPP availability, and adenine nucleotide biosynthesis, which were measured in different rats. The magnitude of these parameters corresponded very closely in each rat organ examined (Figure 2) . The G-6-PDH activity was lower in the myocardium than in the kidney and liver.14 This supports earlier findings obtained in dog heart muscle homogenates,22 in isolated cardiac myocytes from rats,23 and in the rat during development. 24 In the latter study, the activities of both G-6-PDH and 6-PGDH were always lower in the heart than in the liver.
The first and rate-limiting enzyme, G-6-PDH, seems to be responsible for the limited capacity of the oxida- tive PPP in the heart, so that the available pool of PRPP and the rate of adenine nucleotide biosynthesis are very small.4 This limitation can be overcome by ribose, which bypasses the critical step, the G-6-PDH reaction. As a consequence, the PRPP pool and the rate of adenine nucleotide biosynthesis were elevated by ribose (Figure 2 ).6,25 Ribose has been shown to restore, partially or entirely, the adenine nucleotide pool in various pathophysiological situations, such as stimulation with isoproterenol,6 postischemic recovery,7 and myocardial infarction. In skeletal muscle, G-6-PDH activity was even lower than in the heart,26 and adenine nucleotide biosynthesis was not measurable under control in vivo conditions. When ribose was administered, it was of the same order of magnitude as in the heart in the control situation (Figure 2) . The conditions for measuring adenine nucleotide biosynthesis may be different in the isolated rat extensor digitorum longus muscle27 and in the perfused rat hindquarter preparation.28 In these preparations, adenine nucleotide biosynthesis was readily measurable.
That G-6-PDH is the rate-limiting enzyme of the oxidative PPP in the heart is also supported by our results obtained with isoproterenol. This ,B-adrenergic agonist induced a dose-dependent increase in G-6-PDH activity but did not affect 6-PGDH activity (Table 1 ). Parallel to the increase in G-6-PDH activity, the PRPP pool was elevated ( Figure 5 ), and adenine nucleotide biosynthesis was enhanced (Figure 3) . Our time course studies, however, revealed that the temporal relations were more complex. From the data in Figure 3 , it appears that there were two distinct phases subsequent to fl-receptor stimulation: The first phase, lasting about 5 hours, was characterized by the enhancement of glycogenolysis as evidenced by the elevation of cardiac cAMP and G-6-P levels, by the positive chronotropic and inotropic response, by the elevation of the PRPP pool ( Figure 5) , and by the immediate increase in adenine nucleotide biosynthesis. There was no change in G-6-PDH activity (Figure 3 ). During the second phase, after 12 hours subsequent to isoproterenol, glycogenolysis and heart function had become normalized, but adenine nucleotide biosynthesis was still increased, though at a lower level. The PRPP pool was also elevated ( Figure 5 ), and protein synthesis as well as G-6-PDH activity started to increase steeply ( Figure 3) . Thus, the increase in the available PRPP pool and in adenine nucleotide biosynthesis coincided with the stimulation of glycogenolysis during the first phase and with the enhancement of G-6-PDH activity during the second phase.
Since G-6-PDH activity was unchanged during the first phase, a mechanism other than an enhanced flow through the oxidative PPP may be responsible for the increase in the PRPP pool and in adenine nucleotide biosynthesis. One possibility is that not only glycogenolysis but also glycolysis is stimulated by isoproterenol. This could then lead to an increased availability of PRPP through the nonoxidative PPP via the transaldolase and transketolase reactions. The activities of these enzymes were shown to be much higher than those of G-6-PDH and 6-PGDH in muscle.26 Furthermore, the large amounts of NAD+ present in the heart (29) 35 Apart from activation of the adenylate cyclasecAMP system, Ca'+ ions seem also to contribute to the stimulation of G-6-PDH activity. When the calcium antagonists D 600 (gallopamil) and verapamil were applied in combination with isoproterenol or fenoterol, the catecholamine-induced increase in G-6-PDH activity was attenuated by 65% ( Figure 4 ) and 50% (Figure 9 ), respectively. Similarly, D 600 blunted both the isoproterenol-induced increase in cAMP36 and in adenine nucleotide biosynthesis by 50%. 4 The remaining stimulation of G-6-PDH activity occurred independent of the function of the heart: The isoproterenol-mediated stimulation of G-6-PDH activity took place at a time when the positive chronotropic and inotropic effect was over ( Figure  3) . Moreover, the fenoterol-induced increase in heart function was abolished by verapamil to such an extent that heart rate and LV systolic pressure (Figure 8 ) and the pressure-rate product ( Figure 9 ) were even lower than control, yet the G-6-PDH activity was still elevated. Thus, there was a dissociation between function and metabolism of the heart in these experimental conditions.
It is interesting that not only isoproterenol but also clinically applied sympathomimetic substances stimulate the oxidative PPP. Dopamine37 and dobutamine38 were applied for 24 or 48 hours, since the time-course studies with isoproterenol had revealed the peak G-6-PDH activity to be during this period of time (Figure 3 ). These agents act directly at cardiac fl1-receptors. Accordingly, the effect of dopamine on myocardial G-6-PDH activity was prevented by the f1-selective blocker atenolol (Table 3) . Also, sympathomimetic agents that interact with /32-receptors,39 such as fenoterol,40 salbutamol,41 and terbutaline, and are used for the treatment of bronchoconstrictive disease42-stimulated G-6-PDH activity after an in vivo exposure time of 48 hours (Figures 6 and 7) . Considering the high doses that were applied in our studies, this effect may be due to the influence on cardiac /31-receptors. Apart from their positive inotropic effect, all these sympathomimetic agents had metabolic effects that ultimately tend to restore the cardiac ATP pool (Figure 1 ). This can be considered as a beneficial effect in the treatment of heart failure. 43 A final aspect concerns the cellular compartment in which the oxidative PPP is localized within the myocardium. It has been shown in this study that G-6-PDH activity was present in freshly isolated cardiac myocytes and that it was increased about 10-fold after 28 hours of in vivo exposure to a high dose of isoproterenol. Since G-6-PDH activity was lower in isolated cardiac myocytes compared with whole heart, other cell elements in the myocardium must also have this enzyme. The coronary endothelial cells can be excluded as a potential site, since the biosynthesis of adenine nucleotides, which is dependent on the oxidative PPP, was inhibited by isoproterenol.44 A likely cellular compartment may therefore be the connective tissue. Since isoproterenol in the doses applied induces focal myocardial cell lesions,45 the observed increase in G-6-PDH could well have occurred in inflammatory or connective tissue cells. It is known that the oxidative PPP is increased markedly subsequent to experimental myocardial infarction.46 However, when the isoproterenol-induced focal myocardial injury was prevented by simultaneous administration of a calcium antagonist,47 G-6-PDH activity was still enhanced (Figure 4) . Furthermore, the isoproterenol-induced percent increase was much higher in isolated cardiac myocytes than in the whole heart. That the oxidative PPP is active in isolated cardiac myocytes and that it can be altered experimentally has also been shown in a previous study .23 In summary, all 3-adrenergic agonists tested stimulated the oxidative PPP in the rat heart in vivo in a dose-and time-related manner. An increase in the oxidative PPP has also been observed during the development of cardiac hypertrophy due to aortic constriction.3048, 49 Interestingly, other positive inotropic agents such as ouabain (authors' unpublished observations) and triiodothyronine had no effect.30 Therefore, the stimulation of the oxidative PPP seems to be a new metabolic effect that is characteristic for sympathomimetic agents.
